Plumbagin Enhances the Anticancer Effects of PF Chemotherapy via Downregulation of the PI3K/AKT/mTOR/p70S6K Pathway in Human Tongue Squamous Cell Carcinoma

Figure 7

Combined treatment with PB and PF inhibited TSCC xenograft tumor growth in vivo. (a-b) Cal27/CDDP-derived xenograft models via subcutaneous injection into BALB/c nude mice. (c) Tumor weights in the PB + PF group were significantly lower than those in the control group. (d) Tumor volumes in the PB + PF group were significantly lower than those in the control group. (e) No significant changes in body weight were observed in the PB + PF group compared with the control group. (f) Ki67 expression in the PB + PF group was significantly lower than that in the control group. (g) H and E staining verified that the PB + PF group did not induce toxicity in major organs (n = 6/group). PB, plumbagin; PF, cisplatin plus 5-fluorouracil; and TSCC, tongue squamous cell carcinoma.

(a)

(b)

(c)

(d)

(e)

(f)

(g)